HC Wainwright Reaffirms “Buy” Rating for Halozyme Therapeutics (NASDAQ:HALO)

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $70.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $57.94 on Tuesday. Halozyme Therapeutics has a 1-year low of $34.36 and a 1-year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $7.37 billion, a PE ratio of 19.19, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. The firm’s 50 day simple moving average is $51.18 and its 200 day simple moving average is $54.38.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HALO. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. GAMMA Investing LLC increased its stake in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares during the period. Smartleaf Asset Management LLC raised its holdings in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics during the 3rd quarter valued at $57,000. Finally, FSC Wealth Advisors LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter worth $65,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.